| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 03/21/2013 | WO2013038191A2 Anti-cd134 (ox40) antibodies and uses thereof |
| 03/21/2013 | WO2013038156A1 Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile |
| 03/21/2013 | WO2013038022A1 Method for characterizing bacteria by detection of non-structural bacteriophage proteins |
| 03/21/2013 | WO2013038016A2 Monoclonal antibodies for detection of high-risk human papillomavirus oncoprotein e7 |
| 03/21/2013 | WO2013037727A1 B7-h6 therapeutically active monoclonal antibody against b7-h6 polypeptide |
| 03/21/2013 | WO2013037714A1 BIOMARKERS FOR BREAST TUMOURS FROM Hsp70-ASSOCIATED PEPTIDES |
| 03/21/2013 | WO2013037700A1 Human papilloma virus (hpv) e7 is a prognostic marker for prostate cancer |
| 03/21/2013 | WO2013037695A1 Antibodies against e7 protein of human papilloma virus (hpv) |
| 03/21/2013 | WO2013037484A2 Anti-aplhabetatcr antibody |
| 03/21/2013 | WO2013011062A3 Antagonistic antibodies against oscar |
| 03/21/2013 | WO2013009703A3 Antibodies, kit and method for detecting amyloid beta oligomers |
| 03/21/2013 | WO2013007763A9 MODULATORS OF THE NLRP3 INFLAMMASOME IL-1ß PATHWAY FOR THE PREVENTION AND TREATMENT OF ACNE |
| 03/21/2013 | WO2013003641A3 Serpin fusion polypeptides and methods of use thereof |
| 03/21/2013 | WO2012163521A4 Removal of monomeric targets |
| 03/21/2013 | WO2012162257A3 Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers |
| 03/21/2013 | WO2012158989A9 Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation |
| 03/21/2013 | WO2012143497A3 Novel binder-drug conjugates (adcs) and their use |
| 03/21/2013 | WO2012143496A3 Novel binder-drug conjugates (adcs) and their use |
| 03/21/2013 | WO2012114125A3 Treatment and prevention of malaria |
| 03/21/2013 | WO2009155513A3 Immunoglobulins with reduced aggregation |
| 03/21/2013 | US20130074201 Cancer-specific genetic rearrangements |
| 03/21/2013 | US20130074199 Compositions and Methods for Brown Fat Induction and Activity Using FNDC5 |
| 03/21/2013 | US20130072667 Use of rgm and its modulators |
| 03/21/2013 | US20130072666 Antibody Complexes and Methods for Immunolabeling |
| 03/21/2013 | US20130072665 Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9) |
| 03/21/2013 | US20130072664 Human monoclonal antibody having fat-reducing effect |
| 03/21/2013 | US20130072663 Antibodies to Alpha Synuclein |
| 03/21/2013 | US20130072581 Secreted Protein Acidic and Rich in Cysteine (SPARC) Protein SRM Assay |
| 03/21/2013 | US20130071951 Methods and compositions for determining the purity of chemically synthesized nucleic acids |
| 03/21/2013 | US20130071949 IMMUNOASSAY FOR QUANTIFICATION OF AN UNSTABLE ANTIGEN SELECTED FROM BNP AND proBNP |
| 03/21/2013 | US20130071923 Human gm-csf antigen binding proteins |
| 03/21/2013 | US20130071922 Anti-C5 Alpha Antibodies |
| 03/21/2013 | US20130071921 Antibodies specific for dkk-1 and their uses |
| 03/21/2013 | US20130071863 Sulfur-Containing Amino Acid Derivative |
| 03/21/2013 | US20130071859 Methods of Determining Patient Response by Measurement of HER-3 |
| 03/21/2013 | US20130071431 Method for Preserving Polypeptides Using A Sugar and Polyethyleneimine |
| 03/21/2013 | US20130071424 Peptides mimicking hiv-1 viral epitopes in the v2 loop for the gp120 surface envelope glycoprotein |
| 03/21/2013 | US20130071410 Human CGRP Receptor Binding Proteins |
| 03/21/2013 | US20130071406 Methods and Compositions for Treatment of Human Immunodeficiency Virus Infection with Conjugated Antibodies or Antibody Fragments |
| 03/21/2013 | US20130071405 Antibodies to pcsk9 and uses thereof |
| 03/21/2013 | US20130071401 Methods of treating diabetes and compositions capable of same |
| 03/21/2013 | US20130071400 LINGO binding molecules and Pharmaceutical Use Thereof |
| 03/21/2013 | US20130071398 Pharmaceutical composition for treating and/or preventing cancer |
| 03/21/2013 | US20130071397 Inhibitors of vascular endothelial growth factor (vegf) receptors and methods of use thereof |
| 03/21/2013 | US20130071395 Compositions and methods for treating pathologies |
| 03/21/2013 | US20130071390 Method for preparing antibodies having improved properties |
| 03/21/2013 | US20130071388 Method for treating psoriasis |
| 03/21/2013 | US20130071386 Immunoglobulin Formulation and Method of Preparation Thereof |
| 03/21/2013 | US20130071385 Monoclonal antibodies |
| 03/21/2013 | US20130071383 Selective modification of proteins |
| 03/21/2013 | US20130071381 Humanized anti-ccr2 antibodies and methods of use therefor |
| 03/21/2013 | US20130071380 Modulation of pilr to treat immune disorders |
| 03/21/2013 | US20130071379 1b20 pcsk9 antagonists |
| 03/21/2013 | US20130071366 Insulin-like growth factor ii (igf-ii) binding factors |
| 03/21/2013 | US20130071325 Monoclonal antibodies for treatment of cancer |
| 03/21/2013 | US20130071324 Radioactive metal-labeled anti-cadherin antibody |
| 03/21/2013 | US20130071320 Immunotherapy of autoimmune disorders using antibodies which target b-cells |
| 03/21/2013 | CA2848847A1 Anti-cd134 (ox40) antibodies and uses thereof |
| 03/21/2013 | CA2848765A1 Immunotherapy and diagnosis of mucormycosis using coth |
| 03/21/2013 | CA2848611A1 Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile |
| 03/21/2013 | CA2848410A1 Rna engineered t cells for the treatment of cancer |
| 03/21/2013 | CA2848403A1 Hyr1-derived compositions and methods of treatment using same |
| 03/21/2013 | CA2848333A1 B7-h6 therapeutically active monoclonal antibody against b7-h6 polypeptide |
| 03/21/2013 | CA2848209A1 T cell receptors recognizing hla-a1- or hla-cw7-restricted mage |
| 03/21/2013 | CA2848201A1 Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9) |
| 03/21/2013 | CA2847949A1 Anti-.alpha..beta.tcr antibody |
| 03/21/2013 | CA2845807A1 Calibration reagent and method |
| 03/21/2013 | CA2845706A1 Antibodies to pcsk9 and uses thereof |
| 03/20/2013 | EP2570436A1 Use of neutralizing prolactin receptor antibodies in combined hormone therapy |
| 03/20/2013 | EP2570435A1 Use of neutralizing prolactin receptor antibodies for the treatment of endometriosis and andenomyosis |
| 03/20/2013 | EP2570434A2 Neuropilin antagonists |
| 03/20/2013 | EP2570433A1 Neutralizing human antibodies to anthrax toxin generated by recall technology |
| 03/20/2013 | EP2570432A1 Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
| 03/20/2013 | EP2570424A1 OB-Fold used as scaffold for engineering new specific binders |
| 03/20/2013 | EP2570137A2 Antibodies that bind human dendritic and epithelial cell 205 (DEC-205) |
| 03/20/2013 | EP2569632A1 Yeast cell wall components and detection thereof |
| 03/20/2013 | EP2569337A1 Heterodimeric proteins and methods for producing and purifying them |
| 03/20/2013 | EP2569336A1 Enhanced death receptor agonists |
| 03/20/2013 | EP2569335A2 Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists |
| 03/20/2013 | EP2569334A1 RECOMBINANTLY PRODUCED ANTIBODIES TARGETING ErbB SIGNALING MOLECULES AND METHODS OF USE THEREOF FOR THE DIAGNOSIS AND TREATMENT OF DISEASE |
| 03/20/2013 | EP2569333A1 Novel mutated humanized 12g4 antibodies and the fragments thereof against the human anti-müllerian hormone receptor type ii |
| 03/20/2013 | EP2569014A1 Treatment methods |
| 03/20/2013 | EP2569012A2 Anti-fgfr2 antibodies |
| 03/20/2013 | EP2569010A1 High concentration antibody formulations |
| 03/20/2013 | EP2345670B1 Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases |
| 03/20/2013 | CN102985442A Monoclonal antibodies detection methods for enzymes that confer resistance to 2,4-dichlorophenoxyacetic acid in plants |
| 03/20/2013 | CN102985441A Monoclonal antibodies that inhibit the Wnt signaling pathway and methods of production and use thereof |
| 03/20/2013 | CN102985113A Compositions and methods for the diagnosis and treatment of tumor |
| 03/20/2013 | CN102985112A Pharmaceutical composition for treatment and prevention of herpesvirus infections |
| 03/20/2013 | CN102985110A Novel modulators |
| 03/20/2013 | CN102985109A Homodimeric protein constructs |
| 03/20/2013 | CN102985106A Methods and compositions for treating Degos' disease |
| 03/20/2013 | CN102978219A Vibrio cross-protective antigen, and preparation and application thereof |
| 03/20/2013 | CN102977213A Monoclonal antibodies against NKG2A |
| 03/20/2013 | CN102977212A Compositions comprising anti-IGF-1r antibodies and methods for their production |
| 03/20/2013 | CN102977211A Preparation method of rabbit anti-bovine alpha s-casein polyclonal antibody |
| 03/20/2013 | CN102977210A Monoclonal antibody preparation method of huperzine A and enzyme-linked immune detection kit thereof |
| 03/20/2013 | CN102977209A Preparation method and application of multivalent yolk immunoglobulin for preventing and treating bouine mastitis |
| 03/20/2013 | CN102977208A Preparation method, application and medicine composition and preparation of specific egg yolk immunoglobulin (IgY) and acinetobacter baumannii, as well as preparation and kit |
| 03/20/2013 | CN102977180A Method for comprehensive utilization of Cohn component IV |